Why You Should Invest in CBD

Share on facebook
Share on twitter
Share on linkedin
Share on email

Strike while the iron is hot.


Those who invested in CBD a year ago are sitting very comfortable on their stock.

If we look to see how rapidly marijuana laws are changing as an indication of the future. While CBD may not be FDA approved for all use, it is legal, and making strides in medical communities daily.


Many believe that soon it will be on all shelves of grocery and drugs stores. In your food products, skin care lines, sleeping supplements and more. According to Marketwatch.com, “CBD is a very lucrative business because just a small amount of CBD it is quite expensive. Thus making CBD business incredibly lucrative to investors, and shareholders alike.”


These companies are set to explode: Chineseinvestors.com, Inc. (CIIX), GW Pharmaceuticals Plc. GWPH, -0.54% Aurora Cannabis (ACBFF), Cara Therapeutics Inc. (CARA), Zynerba Pharmaceuticals Inc. ZYNE, -4.60%

Chineseinvestors.com, Inc. (CIIX)

Market Cap: $16.65M, current share price: $0.52

ChineseInvestors.com, Inc. is responsible for the online and retail sales of hemp-based health products in the United States and has been building awareness for its ‘Opt Hemp’ brand among Chinese consumers in the U.S. since its establishment in April 2017.

Aurora Cannabis (otcqx:ACBFF)

Market Cap: $8.72B Share Price: $9.10

Micron Waste Technologies Inc. reported positive results from the optimization of the Cannavore™ cannabis waste processing units with Aurora Cannabis Inc.. The Company will now optimize the technology for sub-zero operations, as well as add computerized remote operating capabilities, following which Micron will commence to offer the units commercially.

Cara Therapeutics Inc. CARA, +0.41%

Market Cap: $832.96M, current share price: $21.20

Cara Therapeutics, Inc. is developing product candidates that target the body’s peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis

GW Pharmaceuticals Plc. GWPH, -0.62%

Market Cap: $3.97B, current share price: $140.94

GW Pharmaceuticals plc, is a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant

Zynerba Pharmaceuticals Inc. ZYNE, -3.64%

Market Cap: $117.20M, current share price: $6.65

Zynerba Pharmaceuticals, Inc. focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders.

Leave a Reply